Research institutionUnited Statesc-path.org/program/critical-path-for-alzheimers-disease
The Critical Path for Alzheimer’s Disease (CPAD) Consortium is a pre-competitive research initiative hosted by the Critical Path Institute (C-Path), an independent non-profit organization focused on regulatory science and drug development tools.
Founded in 2008 as the Coalition Against Major Diseases (CAMD) and renamed CPAD, the consortium aggregates de-identified patient-level data from dozens of Alzheimer’s disease (AD) and mild cognitive impairment clinical trials into a standardized database. This resource, mapped to CDISC standards, includes demographic, cognitive, biomarker, and imaging data from over 12,000 patients across more than 30 studies and is accessible to qualified researchers and members.
CPAD develops quantitative disease progression models and clinical trial simulation tools for trial design optimization, patient enrichment, and endpoint selection. These tools have received regulatory endorsements or letters of support from the FDA and EMA. It also leads working groups on tau-PET biomarker harmonization and surrogacy to standardize imaging measures across tracers and cohorts.
Operating globally with headquarters in Tucson, Arizona, CPAD convenes stakeholders from pharmaceutical companies (including Roche/Genentech, Biogen, Eisai, Lilly), regulatory agencies (FDA, EMA), academia, and patient organizations in a neutral forum. It accelerates AD therapeutic innovation by reducing development uncertainty through shared data, modeling, and consensus-driven tools, positioning it as a key player in the pre-competitive AD research ecosystem.
Also known as Coalition Against Major Diseases (CAMD).
None yet. When a new project in the record names CPAD as owner, partner or investor, it shows here.
PrevenTRON Phase III enrollment has started; Phase II TARBELA-AD launched for oral NLRP3 inhibitor RG6434; Brainshuttle trontinemab shows rapid amyloid removal; new Elecsys pTau217/pTau181 data published.
